Mucopolysaccharidosis Type I Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | BioMarin Pharmaceutical, Sanofi, Kyowa Kirin, REGENXBIO, Nippon Shinyaku, IMMUSOFT

The Mucopolysaccharidosis Type I (MPS I) market was valued at USD 149 million in 2025 and is projected to grow at a robust CAGR of 8% during the forecast period (2025–2034). DelveInsight's comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Mucopolysaccharidosis Type I landscape.

By analyzing historical data, current market dynamics, and future projections, DelveInsight equips pharmaceutical companies, investors, and healthcare professionals with actionable intelligence to make informed strategic decisions, identify investment opportunities, optimize product positioning, and plan research and development initiatives effectively.

The MPS I market is increasingly guided by innovative gene therapy strategies and advanced enzyme replacement approaches. ALDURAZYME (BioMarin Pharmaceutical and Sanofi), the only FDA-approved enzyme replacement therapy for Mucopolysaccharidosis Type I, currently leads the treatment landscape, having been approved in the United States in April 2003, followed by approvals in the EU4, the United Kingdom (June 2003), and Japan (2006). Although its patent has expired, no biosimilars or alternative biologics have been approved, underscoring the urgent need for new treatment options.

The Mucopolysaccharidosis Type I market size in the United States accounted for approximately 50 percent of the total market across the 7MM (seven major markets). According to DelveInsight's estimates, in 2024, there were approximately 660 diagnosed prevalent cases of MPS I in the 7MM, with the United States accounting for 36 percent of these cases.

Mucopolysaccharidosis Type I is a rare, inherited neurometabolic disease caused by a deficiency of the alpha-L-iduronidase (IDUA) lysosomal enzyme, resulting in the accumulation of glycosaminoglycans (GAGs) in multiple organs, including the musculoskeletal and central nervous systems, as well as the heart, eyes, and ears. It is estimated to occur globally in approximately 1 in 100,000 live births, with approximately 60 percent of children born with MPS I, which rarely results in survival past the age of 10 when untreated.​

MPS I is classified into three subtypes: Hurler syndrome (IH), Hurler/Scheie syndrome (IH/S), and Scheie syndrome (IS). The disease manifests across a continuum of phenotypes ranging from severe (IH) to intermediate (IH/S) and milder (IS) presentations. Striking clinical features include neurodegeneration, respiratory deterioration, cardiac diseases, and skeletal and joint disorders. Other common symptoms encompass ocular problems, organomegaly, deformative facies, and hearing and visual deficits. In severe cases, GAG storage typically involves the brain and bone, causing progressive neurological disease including cognitive disorders and skeletal diseases such as kyphoscoliosis and dysostosis multiplex.

DelveInsight’s report, “Mucopolysaccharidosis I Market Insights, Epidemiology, and Market Forecast – 2034,” provides a comprehensive analysis of the Mucopolysaccharidosis I landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Mucopolysaccharidosis I market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Mucopolysaccharidosis I market outlook, drug uptake, treatment scenario and epidemiology trends, Click here: Mucopolysaccharidosis I Market Forecast

Some of the Key Facts of the Mucopolysaccharidosis I Market Report:

• Key Mucopolysaccharidosis I Companies: BioMarin Pharmaceutical, Sanofi, Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, REGENXBIO, Nippon Shinyaku, IMMUSOFT, among others.
• Key Mucopolysaccharidosis I Therapies: ALDURAZYME (laronidase), OTL-203, Lepunafusp alfa (JR-171), RGX-111, Iduronidricin genleukocel-T (ISP-001), among others.
• The Mucopolysaccharidosis Type I market is expected to surge due to the launch of innovative therapies addressing the significant limitations of current treatment options, and a shift towards innovative gene and CNS-penetrant therapies which focuses on treatment rather than Mucopolysaccharidosis Type I management.

Mucopolysaccharidosis Type I Overview

Mucopolysaccharidosis Type I (MPS I), also known as Hurler syndrome, is the most common form of mucopolysaccharidosis and accounts for approximately 35 percent of all Mucopolysaccharidosis cases, making it the largest market segment within the broader Mucopolysaccharidosis therapeutics landscape. The disease grows and progresses slowly but severely, causing multisystem involvement affecting skeletal development, neurological function, cardiac health, and respiratory capacity. Early detection and personalized treatment approaches have been shown to significantly improve patient outcomes and quality of life.

Get a Free sample for the Mucopolysaccharidosis I Market Report

Key Trends in Mucopolysaccharidosis Type I Therapeutics Market:

• Rising adoption of gene therapy approaches, particularly hematopoietic stem cell (HSC) gene therapy, is transforming the MPS I treatment paradigm by addressing both somatic and neurological disease components.
• Enzyme replacement therapies with blood-brain-barrier (BBB)-penetrating capabilities are emerging as critical innovations to address the central nervous system (CNS) complications that have historically been a major unmet need in MPS I management.
• Advances in molecular diagnostics and biomarker testing are enabling early diagnosis through expanded newborn screening programs, facilitating timely intervention and improved patient outcomes. The development of combination therapies and next-generation approaches to overcome resistance and maximize treatment efficacy represents a key trend shaping the market. 
• Increased investment in rare disease research and supportive regulatory frameworks, including Fast Track Designations, Orphan Drug Designations, and PRIME status from regulatory agencies, are accelerating the development timeline for promising candidates.
• Enhanced awareness and patient advocacy efforts are driving earlier diagnosis rates and better disease management across all geographic markets.

Mucopolysaccharidosis Type I Epidemiology

The report on Mucopolysaccharidosis Type I (MPS I) epidemiology provides a comprehensive analysis of the disease's prevalence, incidence, and patient demographics. It includes age- and gender-specific distribution, regional and global trends, and data on disease severity classifications. The report also highlights risk factors, disease burden, and projections for future trends, helping stakeholders understand the scope of MPS I and plan targeted interventions, research, and treatment strategies.

Mucopolysaccharidosis Type I Epidemiology Segmentation

The Mucopolysaccharidosis Type I market report proffers epidemiological analysis for the study period 2024–2034 in the 7MM (The United States, EU4 [Germany, Spain, Italy, and France, and the United Kingdom], and Japan) segmented into:

• Mucopolysaccharidosis I Diagnosed Prevalent Cases
• Mucopolysaccharidosis I Severity-specific Diagnosed Prevalent Cases
• Mucopolysaccharidosis I Treated Cases

Download the report to understand which factors are driving Mucopolysaccharidosis Type I epidemiology trends @ Mucopolysaccharidosis Type I Epidemiology Forecast

Recent Developments in the Mucopolysaccharidosis Type I Treatment Landscape

• In July 2025, Orchard Therapeutics announced the successful completion of patient enrollment in its registrational trial of OTL-203, with the last patient treated and enrollment achieved nearly one year ahead of schedule. The primary analysis is anticipated two years post-treatment.
• In March 2025, REGENXBIO Inc. finalized its previously announced strategic partnership with Nippon Shinyaku to develop and commercialize RGX-111 for Mucopolysaccharidosis I (MPS I), in the United States and Asia. Under the agreement, REGENXBIO will receive $110 million at closing and up to an additional $700 million in potential milestone payments, plus meaningful double-digit royalties on net sales.
• At the 21st Annual WORLDSymposium in February 2025, Orchard Therapeutics presented updated findings from a proof-of-concept study on OTL-203, highlighting improvements in neurological, skeletal, and other clinical outcomes. The company plans to submit a US application in 2028, with potential approval expected in 2029 under priority review.
• OTL-203 has received Fast Track Designation (FTD), Orphan Drug Designation (ODD), and Rare Pediatric Disease Designation (RPDD) from the FDA, as well as PRIME status from the EMA.

Mucopolysaccharidosis Type I Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Mucopolysaccharidosis Type I market or expected to get launched during the study period. The analysis covers Mucopolysaccharidosis Type I market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Mucopolysaccharidosis Type I Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Mucopolysaccharidosis Type I Therapies and Key Companies

• ALDURAZYME (laronidase): BioMarin Pharmaceutical/Sanofi
• OTL-203: Orchard Therapeutics/Kyowa Kirin
• Lepunafusp alfa (JR-171): JCR Pharmaceuticals
• RGX-111: REGENXBIO/Nippon Shinyaku

To know more about Mucopolysaccharidosis Type I companies working in the treatment market, visit @ Mucopolysaccharidosis I Clinical Trials and Therapeutic Assessment

Mucopolysaccharidosis Type I Market Drivers

• Increasing prevalence of MPS I globally, driven by expanded newborn screening programs and earlier diagnosis rates.
• Growth of advanced treatment modalities including hematopoietic stem cell gene therapy and blood-brain-barrier-penetrating enzyme replacement therapies
• Advancements in molecular diagnostics and biomarker testing
• Rising healthcare expenditure and government initiatives supporting rare disease care
• Development of combination therapies and next-generation approaches
• Enhanced awareness through patient advocacy organizations and disease-specific registries

Mucopolysaccharidosis Type I Market Barriers

• High cost of advanced gene therapies and enzyme replacement therapies
• Complex clinical trial designs and lengthy regulatory approval processes
• Manufacturing challenges associated with gene therapy production
• Limited awareness and accessibility in emerging market
• Safety concerns and potential adverse events associated with advanced therapies
• Variability in patient response due to genetic heterogeneity and disease phenotype complexity

Scope of the Mucopolysaccharidosis Type I Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain, and the United Kingdom), and Japan)]
• Key Mucopolysaccharidosis Type I Companies: Orchard Therapeutics, Kyowa Kirin, JCR Pharmaceuticals, REGENXBIO, Nippon Shinyaku, IMMUSOFT, and others
• Key Mucopolysaccharidosis Type I Therapies: ALDURAZYME (laronidase), OTL-203, Lepunafusp alfa (JR-171), RGX-111, Iduronicrin genleukocel-T (ISP-001), and others
• Mucopolysaccharidosis Type I Therapeutic Assessment: Mucopolysaccharidosis Type I current marketed and Mucopolysaccharidosis Type I emerging therapies
• Mucopolysaccharidosis Type I Market Dynamics: Mucopolysaccharidosis Type I market drivers and Mucopolysaccharidosis Type I market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Mucopolysaccharidosis Type I Unmet Needs, KOL's views, Analyst's views, Mucopolysaccharidosis Type I Market Access and Reimbursement

Discover more about therapies set to grab major Mucopolysaccharidosis Type I market share @ Mucopolysaccharidosis Type I Treatment Market.